vTv Therapeutics Announces Issuance Of US Patent For Azeliragon As A Treatment Of Glioblastoma To Cantex Pharmaceuticals
Portfolio Pulse from Benzinga Newsdesk
vTv Therapeutics announced the issuance of a US patent for Azeliragon as a treatment for glioblastoma to Cantex Pharmaceuticals. The patent may impact VTVT's stock price.
May 24, 2023 | 1:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
vTv Therapeutics' Azeliragon receives US patent for glioblastoma treatment, potentially impacting VTVT's stock price.
The issuance of the US patent for Azeliragon as a treatment for glioblastoma to Cantex Pharmaceuticals is a positive development for vTv Therapeutics. This news may lead to increased investor interest in VTVT, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100